Xencor (XNCR) Cantor Global Healthcare Conference 2025 summary

Strategic evolution and platform focus

• Advancing from oncology into immunology, leveraging XmAb protein engineering to address unmet needs in autoimmune diseases while maintaining a core in oncology.

• Emphasis on creating differentiated molecules, including bispecific antibodies and optimized monoclonals, to achieve unique clinical positioning.

• Strategic focus on building molecules that reach key clinical inflection points, adapting to opportunities in various therapeutic areas.

• Strong market interest in assets with clear competitive differentiation.

XmAb819 and renal cell carcinoma program

• XmAb819, a bispecific T cell engager targeting ENPP3, is designed for high selectivity in tumor cells with strong expression, minimizing off-target effects.

• Dose escalation data to be presented at the AACR-NCI-EORTC meeting in October, focusing on advanced clear cell renal cell carcinoma.

• ENPP3 expression remains high across all therapy lines, supporting broad applicability in refractory patients.

• Clinical landscape in RCC is complex, with low response rates and limited effective salvage therapies, highlighting the need for new modalities.

• Early data will focus on anti-tumor activity, safety, and dosing strategies to maximize exposure in rapidly progressing patients.

TL1A program and pipeline expansion

• TL1A identified as a promising target for IBD and other indications, with XmAb942 designed for high potency and extended half-life.

• Phase 2b Zenith UC study in ulcerative colitis starting this quarter, with potential expansion into Crohn's and other diseases.

• Bispecific approach with TL1A and IL-23 targets aims to deliver synergistic efficacy and safety, with first-in-human studies planned for 2026.

• Dermatology and other autoimmune indications are under consideration, but initial focus remains on IBD.

• Long-acting antibody design targets 99% inhibition in the gut, supporting every three-month maintenance dosing.